Abstract
Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
CNS & Neurological Disorders - Drug Targets
Title: Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System
Volume: 10 Issue: 5
Author(s): Bradford D. Fischer
Affiliation:
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
Abstract: Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Export Options
About this article
Cite this article as:
D. Fischer Bradford, Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System, CNS & Neurological Disorders - Drug Targets 2011; 10 (5) . https://dx.doi.org/10.2174/187152711796235050
DOI https://dx.doi.org/10.2174/187152711796235050 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Different Levels of Activity in the Left Intraparietal Sulcus Triggered by Lasting and Unlasting Cues in the Posner Task
Neuroscience and Biomedical Engineering (Discontinued) Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine An Updated Patent Review on Ocular Drug Delivery Systems with Potential for Commercial Viability
Recent Patents on Drug Delivery & Formulation Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Current Topics in Medicinal Chemistry The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Involvement of μ-Opioid Receptor in Methamphetamine-Induced Behavioral Sensitization
Current Neuropharmacology A Longitudinal Study of Alterations of S100B, sRAGE and Fas Ligand in Association to Olanzapine Medication in a Sample of First Episode Patients with Schizophrenia
CNS & Neurological Disorders - Drug Targets The Impending Renaissance in Discovery & Development of Natural Products
Current Topics in Medicinal Chemistry Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Evaluation of an Advanced Self Healing and Highly Durable Corrosion Protective Epoxy Coating Modified with Poly(Aniline-co-Pentafluoroaniline)/ ZrO2 Nanocomposite on Mild Steel
Current Smart Materials (Discontinued) PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews The Role of Melatonin in Pancreatic Protection: Could Melatonin be Used in the Treatment of Acute Pancreatitis?
Current Pharmaceutical Design N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry Cigarette Smoke Decreases Salivary 18 kDa Translocator Protein Binding Affinity – in Association with Oxidative Stress
Current Medicinal Chemistry